Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis AS Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8V8 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (FRA:8V8) has a Buyback Yield % of -37.16 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #76 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 84.4%.
Is Genetic Analysis AS's Buyback Yield % too high?
Genetic Analysis AS's current Buyback Yield % is -37.16. Based on the distribution chart, Genetic Analysis AS ranks #76 out of 90 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #76 out of 90 companies for Buyback Yield %. This places Genetic Analysis AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current Buyback Yield % is -37.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current Buyback Yield % of -37.16. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 4.5% above its estimated fair value. The current Buyback Yield % is -37.16. Genetic Analysis AS's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current Buyback Yield % is -37.16 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 4.5% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
Buyback Yield %: -37.16
GF Value™: €0.04 vs. price of €0.04 (4.5% above fair value)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
39GF Score
Get the complete analysis for FRA:8V8
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
